openPR Logo
Press release

In safe hands with the GLP checklist

07-30-2018 04:45 PM CET | Science & Education

Press release from: BINDER GmbH

The "Good Laboratory Practice" regulatory mandate (GLP for short) was introduced in 1978 after the FDA (U.S. Food and Drug Administration) had already identified significant deficiencies in toxicological studies in the years preceding. The German Chemicals Act was introduced in an effort to ensure that newly approved drugs for human consumption really are safe and minimize any and all risks.
The values of transparency, traceability, assignment of responsibilities, and safekeeping are particularly important in this context. The GLP also checks personal, organizational, and spatial requirements before approving a new drug.
To achieve GLP compliance, specific requirements must be met by the laboratory units (e.g., climate chambers) used in the development of the drugs concerned. Maintenance documents and repair documents must be available to consult when a new drug is being tested. To ensure adherence to all rules and regulations on the unit side during the approval process, BINDER has developed a very helpful checklist for its customers. The checklist guides users through the most important points that are relevant to the compliance of their workflows. Questions include, for example: Is a continuous CO2 supply ensured? Are there back-up chambers available for emergencies? Has a cleaning plan or a maintenance plan been drawn up? All of these questions will help users who are working with a simulation chamber and wish to ensure compliance with the quality guidelines of the GLP regulation.

BINDER temperature, climate, and environmental simulation chambers are the centerpieces of modern laboratories. Designed to meet the highest demands in scientific and industrial fields, they enable the accurate simulation of biological, chemical, and physical environmental conditions. With cutting-edge technology and pioneering innovations, BINDER develops products that provide real added value for the customer. We apply our expertise and feel for the requirements of dynamic, day-to-day work in research facilities to support the widest range of projects and processes in an optimum way. After all, our aim is nothing less than making a contribution to the health, quality of life, and safety of people.

Anne Lenze
PR und Event Specialist

BINDER Central Services GmbH & Co. KG
Im Mittleren Ösch 5
D-78532 Tuttlingen

Phone: +49 7462 / 2005 - 632
Fax: +49 7462 / 2005 - 93 632

E-Mail: Anne.Lenze@binder-world.com
www.binder-world.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release In safe hands with the GLP checklist here

News-ID: 1153087 • Views: 459

More Releases from BINDER GmbH

A new innovation from BINDER: The fail-safe function
BINDER incubators are the best on the market. Why is this? There is a simple answer in the first instance: Because they are constructed in as straightforward a way as possible, they are incredibly reliable. The risk of the cultures inside a BINDER incubator becoming contaminated is reduced to a minimum. But BINDER customers have high standards and want to know more about the details. This is exactly where the
Cocoa beans hitting the spot
The USA-based company Seguine Cacao Cocoa & Chocolate Advisors carries out extensive research into studying and assessing cocoa beans and their flavors. Cocoa beans are his life: When it comes to evaluating the quality and flavor of cocoa beans and chocolate, Ed Seguine is the leading specialist in the field. Ed Seguine is the chairman of various international organizations of countries that produce and import cocoa and sits on several committees.
Energy storage device load tests
Stationary energy storage devices and electric vehicles of every type – from electric bikes to electric wheelbarrows – are in demand like never before. The manufacturers of components for the production of high-voltage batteries have been enjoying an ever-increasing level of demand and thus produce cells and modules which can later be integrated into the battery systems. The cells are interconnected in a cell network, resulting in a module; several
New MB2 controller from BINDER increases efficiency of constant climate chambers
What makes our new MB2 program controller so special is its intuitive operation on the touch display. The new MB2 program controller from BINDER – the world's largest specialist manufacturer of simulation chambers for scientific and industrial laboratories – enables greater efficiency in use thanks to its innovative features. What makes the clear 5.7" touch screen of the KMF and KBF Series constant climate chambers so special is its intuitive operation.

All 5 Releases


More Releases for GLP

GLP-1 Receptor Agonist Market Size, Share Analysis- 2026 | Key Segments, Benefit …
GLP-1 stands for glucagon-like peptide, a type of hormone known as an incretin hormone that is lower than normal in people with type 2 diabetes. GLP-1 receptor agonists belong to a class of medications known as incretin mimetics that help the pancreas to release the optimal amount of insulin, a hormone that transports glucose (sugar) to tissues in the body where it can be used for energy. The specific role
Glucagon Like Peptide-1 (GLP-1) Agonists Market - key players covered:GSK, Sanof …
Los Angeles, United State, –The report titled Global Glucagon Like Peptide-1 (GLP-1) Agonists Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer
Glucagon-Like Peptide-1 (Glp-1) Analogs Market : Deep Analysis by Production Ove …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
The Global Report Focuses on Glucagon Like Peptide-1 (GLP-1) Agonists Market 201 …
"The Report Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report is a professional and in-depth study on the current state of the Glucagon like peptide-1 (GLP-1) agonists industry. The report provides a basic overview of the industry including definitions, classifications, applications and
Sysmex Europe and GLP Systems to attend Euromedlab
Norderstedt, Germany, 21 May 2013 – Healthcare solution specialist Sysmex Europe and lab automation experts GLP Systems recently announced their long-term cooperation in the field of laboratory automation. Now both companies are attending Euromedlab in Milan from 19-23 May – and are looking forward to answering any queries. With a brand new transport concept, modular solutions and real freedom from manufacturers, they are confident they are introducing a game changer
Pharmacelsus' GLP implementation exemplary for European CROs
Scientists of the European Center for Validation of Alternative Methods (ECVAM) attended a GLP workshop at Pharmacelsus GmbH Saarbrücken, 4. Juni 2009 - Pharmacelsus, a CRO specialized in preclinical test services, obtained GLP-certification covering the complete portfolio in November 2008. The company is not only able to perform accompanying analytical services for clinical studies in addition to its preclinical services, but also decided to share its knowledge on the GLP